title: A randomized controlled trial of NuvaRing versus combined oral contraceptive pills for pretreatment in in vitro fertilization cycles.
abstract: OBJECTIVE
  To determine whether use of the NuvaRing (Merck) for pretreatment in IVF cycles would result in better cycle control and patient satisfaction versus a 30-μg oral contraceptive (OC) pill.
  
  
  METHODS
  A prospective randomized, controlled study.
  
  
  METHODS
  An academic, hospital-based fertility clinic in Toronto, Canada.
  
  
  METHODS
  Patients 18-37 years old, undergoing their first IVF or IVF/intracytoplasmic sperm injection (ICSI) cycle.
  
  
  METHODS
  OC versus NuvaRing for IVF pre-treatment.
  
  
  METHODS
  Patient satisfaction, ovarian suppression, and IVF cycle outcomes.
  
  
  RESULTS
  Demographic data were similar in both groups. There were no significant differences in side effects between the NuvaRing and OC pill group with the exception of more breast discomfort in the OC pill group. There were no differences in the protocols, days of stimulation, and number of oocytes between the groups. Patients in the OC pill group had more embryos on day 3 and more patients had excess embryos for freezing. The number of embryos transferred and clinical pregnancy rates (PR) were similar between the two groups, although more patients in the NuvaRing group had cycles cancelled for poor stimulation.
  
  
  CONCLUSIONS
  There was no significant benefit in patient tolerability or side effects with the NuvaRing versus the OC pill for IVF pretreatment; however, side effects overall were low in both groups. Clinical PRs were similar; however, the NuvaRing group had more cancelled cycles and fewer excess embryos for freezing.
  
  
  BACKGROUND
  #NCT01298128.
authors: Centre for Fertility and Reproductive Health, Mount Sinai Hospital, Toronto, Ontario, Canada. kliu@mtsinai.on.ca
authors: Kimberly E
authors: KE
authors: Liu
authors: Munirah
authors: M
authors: Alhajri
authors: Ellen
authors: E
authors: Greenblatt
mesh_terms: D000293:Adolescent; D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D017135:Desogestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D010048:Ovarian Cysts / Q000517:prevention & control; D010053:Ovary / Q000187:drug effects; D017060:Patient Satisfaction; D011247:Pregnancy; D018873:Pregnancy Rate; D055815:Young Adult
chemical_list: D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; C516519:NuvaRing; D004997:Ethinyl Estradiol; D017135:Desogestrel